Does the Rotigotine Patch (Neupro®) Treat or Prevent Augmentation in Restless Legs Syndrome (RLS)?

Transdermal rotigotine (Neupro® patch) is a dopamine agonist drug in the treatment of restless legs syndrome (RLS) often touted to treat or prevent augmentation. ‪@andyberkowskimd‬ of ReLACS Health analyzes whether this 24-hour medicine really does mitigate the effects of augmentation in RLS.

To better understand the phenomenon of augmentation, watch this video:
   • What is Augmentation in Restless Legs...  

For additional information on why dopamine agonists are bad for RLS, read this blog post:
https://www.relacshealth.com/blog/v3h...

In this video, ‪@andyberkowskimd‬ covers the following:
- Summary of augmentation
- Why dopamine agonists are NOT recommended in the treatment of RLS, as evidenced in the upcoming 2024 Clinical Guidelines by the American Academy of Sleep Medicine
- The reasoning behind why this drug may cause less augmentation than its siblings pramipexole and ropinirole
- How drug-funded studies and researchers with financial relationships to the manufacturer may influence the interpretation of trials
- The 2011 study from Oertel et al. showing signficant augmentation: https://www.thelancet.com/journals/la...
- The 2017 Trenkwalder study testing rotigotine in those with RLS who already have augmentation and how the conclusions are misleading: https://www.sciencedirect.com/science...
- Unique challenges for patients who want to survive augmentation from rotigotine patch and get off the medication

These videos are for general medical information only, but for those who live in or near Michigan, Ohio, or Florida, you can hire ‪@andyberkowskimd‬ ReLACS Health as your personal augmentation exterminator. He has successfully treated a few hundred individuals with augmentation from dopamine agonists like the rotigotine patch by offering an RLS Augmentation Management Program for those who need more personalization, time, and expertise. Go to https://www.relacshealth.com/ to schedule your consultation now.